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Abstract
The coronavirus disease 2019 (COVID-19) pandemic has resulted in reorganization of
healthcare settings affecting the delivery of clinical care to patients with spinal mus-
cular atrophy (SMA). There is a concern that patients with SMA may be at increased
risk of manifesting severe symptoms of COVID-19. Currently approved therapies for
SMA improve survival and motor function; however, their delivery requires an
increased exposure to the health system and a dedicated healthcare team. In this
study, we discuss consensus recommendations pertaining to care of SMA patients
during the pandemic. We highlight that SMA treatments should not be perceived as
elective. Decisions regarding the delay of treatments should be made with consider-
ation of the potential risks of COVID-19 exposure and the risk of that delay. We
emphasize the importance of collaborative treatment decisions between the patient,
family, and healthcare provider, considering any geographic- or institution-specific
policies and precautions for COVID-19.
Abbreviations: CSF, cerebrospinal fluid; COVID-19, corona virus disease 2019; NBS, newborn screening; SMA, spinal muscular atrophy.
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1 | INTRODUCTION
Coronavirus disease 2019 (COVID-19) caused by the severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) is a pandemic and
public health emergency. The virus spreads efficiently and rapidly
from person to person, and COVID-19 symptoms include fever,
cough, fatigue, shortness of breath, sore throat, headache, diarrhea,
and reduced taste sensation. Severe manifestations, including pneu-
monia, acute respiratory distress syndrome, and death are more com-
mon in older patients and those with medical co-morbidities.1–3
Nevertheless, several unexpected deaths have been reported in previ-
ously healthy young adults and teenagers.4,5 A recent US Centers for
Disease Control and Prevention mortality and morbidity weekly
report note that the majority of hospitalized children with COVID-19
in the United States for whom the information was available had one
or more underlying medical conditions such as chronic lung disease,
cardiovascular disease, and immunosuppression.6 Management is sup-
portive as there is no specific antiviral treatment currently available.
Social distancing, the most important intervention to limit the spread
of COVID-19,6–8 has necessitated reorganization of healthcare prac-
tice. Though emergent and urgent care continue to be provided to
patients in hospital and office settings, elective and nonurgent ser-
vices are now being provided by telehealth or are being rescheduled.9
Currently available US Food and Drug Administration-approved
therapies for spinal muscular atrophy (SMA), nusinersen and
onasemnogene abeparvovec-xioi,10–12 are life altering and are res-
haping the natural history of the disease, resulting in improved sur-
vival and motor function. These treatments, however, are not a cure,
and patients continue to live with substantial comorbidity, especially
symptomatic infantile onset patients who may have pulmonary com-
promise and require daily supportive care.13 Patients with SMA are at
increased risk of respiratory infections in general, and may be at an
increased risk of manifesting severe symptoms of COVID-19. Cur-
rently, there are no data on how the COVID-19 public health emer-
gency and resultant healthcare restructuring have impacted the care
of SMA patients. Both approved treatments require an increased
exposure to the health system around their delivery. Peer-reviewed
published literature pertaining to COVID-19 and SMA is lacking.
We assembled an expert panel of neuromuscular specialists to provide
recommendations related to SMA care during this public health emergency.
Expert leaders in SMA fromacross theUnited States andEuropewere iden-
tified and invited to join the panel. The primary mode of communication
was email for thorough point-by-point review to reach a consensus. There
were no dissenting opinions with regard to the final recommendations. This
report, therefore, reflects the consensus opinion of the authors.
First and foremost, patients with SMA and their families should fol-
low national, and local guidelines as well as any additional recommenda-
tions for people at risk for serious illnesses from COVID-19.14,15
Patients and families should also follow the guidelines pertaining to
COVID-19 at the institutions where they receive their health care.
Surging COVID-19 rates are placing a tremendous burden on
the healthcare system and healthcare providers, resulting in inter-
ruption of elective and/or nonemergent services and procedures. In
some instances, this has interfered with planned treatments for
SMA patients. SMA treatments are critical to the health and well-
being of these patients and should not be perceived as elective or
nonurgent. This is especially true for young children with infantile
onset SMA.
Nusinersen is given intrathecally with the recommended schedule
of four loading doses in the first 2 months followed by maintenance
doses every 4 months. The US package insert addresses missed
nusinersen dosing, noting that if a loading dose is delayed or missed,
administer it as soon as possible, with at least 14 days between doses,
and continue dosing as prescribed. If a maintenance dose is delayed
or missed, administer as soon as possible and continue dosing every
4 months.10
In response to a request for more information from Biogen
around this issue, the company was able to share pharmacokinetic
modeling data based on cerebrospinal fluid (CSF) and plasma samples
from 370 patients who participated in the clinical development pro-
gram (Biogen data on file; personal communication by means of email
and telephone call). Higher nusinersen CSF exposure correlated with
greater efficacy in motor outcome scales as well as greater decline in
neurofilament levels. To maintain higher CSF exposure, the drug
should be administered every 4 mo.16–18 Based on the modeling in
the maintenance phase, a one-time delay of 1 month results in
approximately a 10% decrease in CSF exposure. If the patient con-
tinues with the original maintenance dosing schedule, the CSF steady
state is restored. As an example, if a patient misses a dose at 4 months
and instead receives it at 6 months, the subsequent dose of
nusinersen would be given 2 months later as originally scheduled and
the CSF steady state exposure is restored. If, instead, the original dos-
ing timeline is altered, and the subsequent dose is given 4 months
after the delayed dose, there is a prolonged delay to restore CSF
steady state exposure. Every effort should be made to give a missed
dose of nusinersen as soon as possible, and maintain the original dos-
ing timeline to maximize the benefit of treatment.
Onasemnogene abeparvovec-xioi gene transfer is administered as
a onetime intravenous infusion over 60 min followed by a few hours
of observation in a controlled setting in the hospital, then several
weeks of careful outpatient management and laboratory monitoring
while immune-suppressed from corticosteroid treatment. Patients
with SMA who receive onasemnogene abeparvovec-xioi require oral
corticosteroids for at least 2 mo. Patients on corticosteroids should be
advised not to discontinue these unless specifically discussed with,
and approved by, their treating neurologist.
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Corticosteroid-treated patients and their families should be extra-
vigilant in practicing social distancing and other recommended precau-
tionary measures. Gene transfer therapy also necessitates frequent
laboratory monitoring for liver function abnormalities, elevated tropo-
nin, and thrombocytopenia. Adjustments to the standard monitoring
schedule should be made only after discussion with the treating neu-
rologist. Alternate options, such as home blood draws and telemedi-
cine visits, if clinically appropriate should be considered to minimize
exposures.
SMA treatments require a team of dedicated healthcare person-
nel and a secure setting, which might be challenging during a pan-
demic. We strongly recommend that healthcare providers work
collaboratively to avoid treatment delays. Early and uninterrupted
treatment, particularly for children with infantile onset SMA, leads to
better outcomes.16,18–20 We emphasize that treatment decisions
should be individualized and made cohesively between the patient,
family, and healthcare provider, taking into account any geographic-
or institution-specific policies and precautions for COVID-19.
Insurance providers typically require standardized physical ther-
apy assessments before and on a regular basis following or during
treatment to document the impact of such treatment. We believe that
these assessments should appropriately be deferred to minimize
exposure of these fragile patients; partial functional assessments by
means of telemedicine may be feasible in some care contexts. We rec-
ommend that coverage for nusinersen and onasemnogene
abeparvovec-xioi should be provided without interruption even if for-
mal clinical and physical therapy assessments are limited. Patients’
neurologists may discuss these needs with third-party payers. The
clinical urgency of ongoing physical, occupational, and speech thera-
pies should be evaluated on a case-by-case basis and their suspension
or continuation agreed upon between providers and their patients.
Newborn screening (NBS) programs have allowed pres-
ymptomatic identification and treatment of SMA patients, dramati-
cally improving outcomes.21 NBS for SMA is currently practiced or
piloted in more than 30 states in the United States.22 The full impact
of the COVID-19 pandemic on the SMA NBS programs is unclear.
However, this impact may include delay in implementing NBS pro-
grams in some states as healthcare resources are diverted; there may
limited ability to arrange face to face patient evaluations and blood
draws for testing while many medical practices severely limit
in-person evaluations or transition to telehealth.9 We continue to rec-
ommend urgent evaluation of infants with SMA identified by NBS
with rapid initiation of treatment while following the regional and
institutional policies pertaining to the public health emergency and
maximizing the safety of patients and caregivers.
In summary, the COVID-19 pandemic presents tremendous chal-
lenges to the healthcare community, and disease-specific recommen-
dations are rapidly evolving. We emphasize that: • SMA treatments
should not be considered elective and should not be delayed or inter-
rupted if at all possible. • It is important to resume the original sched-
ule of nusinersen after a delayed dose. • Standardized physical
therapy assessments to maintain insurance coverage for SMA treat-
ments should be flexible.
We recommend strict adherence to established policies per-
taining to the COVID-19 response and recommend that healthcare
providers work closely with local and institutional authorities to
ensure timely and uninterrupted care for patients with SMA taking
into account the potential risks of COVID-19 exposure.
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